System is positioned to become the go-to player in the $163B peptide market still searching for a leader as the FDA expands access to regulated compounds
SAN FRANCISCO, Sept. 9, 2026 — System, the vertically integrated peptide platform connecting patients with licensed U.S. clinicians and pharmacy-grade compound treatments, today announced $20M in new funding to accelerate its mission of becoming the definitive, trusted name in peptides. Funding comes from Patron Fund, Will Ventures, Vine, Courtside, Daybreak, SV Angel, and RiverPark Ventures. The fresh capital will give more people access to what has historically been reserved for a select group of patients.
Peptides have moved from niche biohacker interest to a mainstream wellness category, with the global peptide therapeutic market estimated at $140 billion in 2025 and projected to reach $163 billion in 2026. Despite a rising adoption of the longevity drugs known to support everything from anti-aging and skin rejuvenation to weight loss management, muscle growth, recovery, and energy enhancement, peptides have historically been costly, unregulated, and largely inaccessible. Now, on the heels of the FDA’s vote to add six reviewed peptides to the list of substances licensed compounding pharmacies can legally prepare, peptides are moving toward a more regulated, legitimate distribution model to serve the growing number of use cases.
System has been building the infrastructure to own the peptide supply chain as it enters a new era of regulation and access. The platform pairs patients with U.S.-licensed clinicians who evaluate individual health history and prescribe personalized peptide protocols, compounded by certified American pharmacies and shipped from lab to door. Differentiating itself from other suppliers and clinicians, System takes ownership by acquiring every link in the peptide supply chain, with a compounding pharmacy in its network and a raw-ingredient (API) manufacturer on its roadmap. Transparency is core to System’s operating model, with patients and regulators having visibility into what goes into every product and transaction: every product is third-party lab tested, clinicians are background-checked and NPDB-reviewed, and each treatment is sourced through FDA-registered U.S. compounding pharmacies.
“My vision was never to be another DTC telehealth brand, but to own more of the stack and build the foundation this category needs as it moves into the mainstream,” says Adam Steinle, Founder and CEO of System. “We want to be category definers and the solution Americans use and trust for their long-term health. This funding signals that we’re building a company that is filling the gap between concierge clinics and research-grade access that no single platform currently owns.”
“Peptides are moving from the edges of wellness into mainstream consumer culture. As healthcare becomes more personal, and increasingly part of how people express their identity, the category-defining companies will be built by founders who understand that trust, quality and brand are inseparable. Adam understood this consumer shift better than anyone. System is building the trusted consumer company that can define this category,” says Amber Atherton, Partner at Patron.
About System
System is a vertically integrated peptide platform delivering science-backed, physician-guided treatments through licensed U.S. clinicians and certified American compounding pharmacies. System’s peptide offerings include Glutathione, MIC+B12, NAD+, and Sermorelin to support energy, recovery, metabolism, muscle, skin, and healthy aging. Every medication is third-party lab-tested and shipped free within two days. Available in all 50 U.S. states, subject to state telehealth regulations. Learn more at systemlabs.com.
SOURCE System
